Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wisconsin Alumni Research Foundation

This article was originally published in Start Up

Executive Summary

Founded in 1925 to administer the vitamin D patent portfolio of University of Wisconsin, Madison professor Harry Steenbock, the Wisconsin Alumni Research Foundation was considered a model for the Bayh-Dole Act, which gave institutions title and rights to their federally funded inventions, and also the responsibility to actively commercialize them, consistent with the public interest. WARF's licensing activities have included the development of blood anti-coagulants, leading to Coumadin, another generation of patents on pharmaceutical use of vitamin D analogs, and the medical imaging technology digital subtraction angiography. Since the passage of Bayh-Dole, WARF has added to its licensing portfolio, among other inventions, MRI imaging techniques, the so-called "UW Solution" for preserving organs for transplantation, and core patents on the use of primate and human embryonic stem cells.

You may also be interested in...



Understanding How To Develop BTK Inhibitors In MS Is Evolving

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel